Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jacob Leet

Optometrist Bentonville, AR Doctor of Optometry

NPI 1376991117 CMS profile 1652677

2300 Se J St, Bentonville, AR 72712

Open in the dashboard

General payments

$1,300

48 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jacob Leet of Bentonville, AR is reported in the CMS Open Payments database as having received $1,300 across 48 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $231 3
2024 General $108 3
2023 General $42 2
2022 General $144 7
2021 General $132 7
2020 General $187 9
2019 General $457 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jacob Leet
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Jacob Leet were reported at $231. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Jacob Leet Optometrist median Middle half National median
2019 $457 $159 $67–$371 $163
2020 $187 $72 $29–$165 $114
2021 $132 $125 $46–$292 $132
2022 $144 $162 $66–$374 $149
2023 $42 $177 $72–$406 $160
2024 $108 $188 $77–$427 $164
2025 $231 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $523 26 payments
  2. Optovue, Inc. $222 4 payments
  3. TissueTech, Inc. $183 3 payments
  4. ABB Con-Cise Optical Group LLC $72 2 payments
  5. CooperVision Inc. $57 2 payments
  6. Allergan Inc. $54 3 payments
  7. Marco Ophthalmic, Inc. $52 2 payments
  8. Bausch & Lomb Americas Inc. $43 2 payments
  9. Sight Sciences, Inc. $43 1 payment
  10. AbbVie, Inc. $19 1 payment
  11. Other $31 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,300 48 payments
Products named General payments · program years 2019–2025
  1. DAILIES $406 20 payments
  2. XR $222 4 payments
  3. CONTACT LENS $72 2 payments
  4. SPECTACLE LENSES $72 2 payments
  5. Precision 1 $46 2 payments
  6. TEARCARE SYSTEM $43 1 payment
  7. RESTASIS MULTIDOSE $42 2 payments
  8. MyDay Contact Lens $41 1 payment
  9. OPD-III $39 1 payment
  10. VUITY $32 2 payments
  11. Other $196 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

471

Median for Optometry: 120

Drug cost

$29,952

Median for Optometry: $8,864

Branded share of claims

15.1%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 15 $15,515
Cyclosporine Generic 12 $7,866
Latanoprost Generic 240 $1,817
Prednisolone Acetate Generic 53 $1,431
Loteprednol Etabonate Generic 14 $1,410
Tobramycin-Dexamethasone Tobramycin/Dexamethasone Brand 29 $958
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 27 $429
Timolol Maleate Generic 62 $283
Dorzolamide Hcl Generic 19 $243

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$78,582

Medicare's payments for the services billed

Medicare patients

756

Average age 75

Services billed

1,490

454 women, 302 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Diabetes 29%
Ischemic heart disease 19%
Atrial fibrillation 16%
Chronic kidney disease 16%
Depression 16%
COPD 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

48 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record